KR101944263B1 - 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체 - Google Patents

에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체 Download PDF

Info

Publication number
KR101944263B1
KR101944263B1 KR1020157000608A KR20157000608A KR101944263B1 KR 101944263 B1 KR101944263 B1 KR 101944263B1 KR 1020157000608 A KR1020157000608 A KR 1020157000608A KR 20157000608 A KR20157000608 A KR 20157000608A KR 101944263 B1 KR101944263 B1 KR 101944263B1
Authority
KR
South Korea
Prior art keywords
ser
leu
gly
thr
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157000608A
Other languages
English (en)
Korean (ko)
Other versions
KR20150043289A (ko
Inventor
쿠안 유안
티아닝 장
웬신 루오
이신 첸
준 장
닝샤오 시아
Original Assignee
시아먼 유니버시티
양셍탕 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시아먼 유니버시티, 양셍탕 컴퍼니 리미티드 filed Critical 시아먼 유니버시티
Publication of KR20150043289A publication Critical patent/KR20150043289A/ko
Application granted granted Critical
Publication of KR101944263B1 publication Critical patent/KR101944263B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5761—Hepatitis B
    • G01N33/5764—Hepatitis B surface antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/02—Hepadnaviridae, e.g. hepatitis B virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
KR1020157000608A 2012-06-11 2013-06-06 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체 Active KR101944263B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210190329 2012-06-11
CN201210190329.X 2012-06-11
PCT/CN2013/076832 WO2013185558A1 (zh) 2012-06-11 2013-06-06 用于治疗hbv感染及相关疾病的多肽及抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187034832A Division KR102106782B1 (ko) 2012-06-11 2013-06-06 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체

Publications (2)

Publication Number Publication Date
KR20150043289A KR20150043289A (ko) 2015-04-22
KR101944263B1 true KR101944263B1 (ko) 2019-02-01

Family

ID=49757513

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157000608A Active KR101944263B1 (ko) 2012-06-11 2013-06-06 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체
KR1020187034832A Active KR102106782B1 (ko) 2012-06-11 2013-06-06 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187034832A Active KR102106782B1 (ko) 2012-06-11 2013-06-06 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체

Country Status (11)

Country Link
US (2) US9751914B2 (enExample)
EP (2) EP2860188B1 (enExample)
JP (1) JP6440259B2 (enExample)
KR (2) KR101944263B1 (enExample)
CN (2) CN103483421B (enExample)
AU (1) AU2013276015B2 (enExample)
BR (2) BR112014030797A2 (enExample)
CA (2) CA2943258C (enExample)
ES (2) ES2843675T3 (enExample)
IN (1) IN2014DN10288A (enExample)
WO (1) WO2013185558A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013276015B2 (en) * 2012-06-11 2017-04-20 Xiamen University Polypeptides and antibodies for treating HBV infection and related diseases
CN107001429B (zh) * 2014-11-28 2022-01-04 赛特瑞恩股份有限公司 乙型肝炎病毒表面抗原的表位及与其特异性结合以中和乙型肝炎病毒的结合分子
WO2017059813A1 (zh) 2015-10-09 2017-04-13 厦门大学 抗乙肝表面抗原的抗体及其用途
WO2018064602A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Chimeric antigen receptor therapy with reduced cytotoxicity for viral disease
KR102358577B1 (ko) 2017-02-17 2022-02-04 시아먼 유니버시티 타겟 폴리펩티드를 제시하는 펩티드 캐리어 및 이의 용도
KR20200010217A (ko) * 2017-04-07 2020-01-30 시아먼 유니버시티 Ｂ형 간염 감염 및 관련 질병의 치료를 위한 항체
CN109718364A (zh) * 2017-10-27 2019-05-07 上海贺普药业股份有限公司 充分剂量条件下治疗乙肝病毒相关肝病的药物和方法
JP7490574B2 (ja) * 2018-05-31 2024-05-27 ノバルティス アーゲー Ｂ型肝炎抗体
KR102084912B1 (ko) * 2019-01-17 2020-03-05 주식회사 녹십자 B형 간염 바이러스 표면 항원의 입체 에피토프 및 이에 특이적으로 결합하는 항체
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
US20220251173A1 (en) * 2019-05-23 2022-08-11 Xiamen University Anti-hepatitis b virus antibodies and use thereof
EP4458975A3 (en) 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
CN111187349A (zh) * 2019-10-30 2020-05-22 四川迈克生物新材料技术有限公司 单克隆抗体的制备方法
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN113717283B (zh) * 2020-05-25 2023-05-26 厦门万泰凯瑞生物技术有限公司 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
CN111879932B (zh) * 2020-06-24 2022-09-27 南方医科大学南方医院 乙型肝炎病毒(hbv)特异性b细胞表位检测方法及其应用
CN115246881B (zh) * 2021-02-02 2025-04-11 浙江理工大学 一种抗HBsAg鲨鱼单域抗体或其抗原结合片段及其应用
CN113234143B (zh) * 2021-05-10 2021-12-14 合肥金域医学检验实验室有限公司 一种快速检测病毒的核酸抗体试剂盒
CN114671947B (zh) * 2022-02-28 2024-04-09 中国科学院生物物理研究所 乙肝病毒不同亚型表面s蛋白高亲和力纳米抗体及其应用
CN116162153B (zh) * 2022-09-01 2024-09-10 复旦大学附属中山医院 一种乙肝病毒表面抗原的单克隆抗体及其应用
CN116751262B (zh) * 2023-07-31 2024-09-06 重庆医科大学国际体外诊断研究院 靶向乙型肝炎病毒核心蛋白的多肽及其应用
CN119161462B (zh) * 2024-10-09 2025-08-19 深圳市第三人民医院(深圳市肝病研究所) 一株乙型肝炎病毒核心蛋白的单克隆抗体cAbD4及其制备与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004103A1 (en) 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
WO1997039029A2 (en) * 1996-04-18 1997-10-23 Abbott Laboratories An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
WO2001027281A1 (en) * 1999-10-08 2001-04-19 Celltech Pharma Europe Limited Designing immunogens
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7144712B2 (en) * 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
JP4948783B2 (ja) * 2005-05-18 2012-06-06 シスメックス株式会社 抗ＨＢｓモノクローナル抗体
CN101606066A (zh) * 2006-10-30 2009-12-16 株式会社先端生命科学研究所 乙型肝炎病毒表面抗原的分析方法
CN101748129A (zh) * 2008-12-04 2010-06-23 上海裕隆临床检验中心有限公司 人源乙肝病毒表面抗体的制备方法
AU2013276015B2 (en) * 2012-06-11 2017-04-20 Xiamen University Polypeptides and antibodies for treating HBV infection and related diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985004103A1 (en) 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
WO1997039029A2 (en) * 1996-04-18 1997-10-23 Abbott Laboratories An antigenic epitope of the a determinant of hepatitis b surface antigen and uses thereof

Also Published As

Publication number Publication date
JP2015522563A (ja) 2015-08-06
CN106046155A (zh) 2016-10-26
CA2943258A1 (en) 2013-12-19
AU2013276015A1 (en) 2014-12-18
IN2014DN10288A (enExample) 2015-08-07
US9751914B2 (en) 2017-09-05
ES2834072T3 (es) 2021-06-16
EP3308798B1 (en) 2020-09-09
KR102106782B1 (ko) 2020-05-07
KR20190011247A (ko) 2019-02-01
EP3308798A2 (en) 2018-04-18
AU2013276015B2 (en) 2017-04-20
EP2860188A4 (en) 2016-04-27
ES2843675T3 (es) 2021-07-20
CA2876020A1 (en) 2013-12-19
EP3308798A3 (en) 2018-05-30
BR122020023349B1 (pt) 2023-02-07
CN103483421A (zh) 2014-01-01
US20150246948A1 (en) 2015-09-03
CN106046155B (zh) 2019-11-22
CN103483421B (zh) 2019-10-22
EP2860188A1 (en) 2015-04-15
EP2860188B1 (en) 2020-10-21
WO2013185558A1 (zh) 2013-12-19
US10246494B2 (en) 2019-04-02
HK1203978A1 (en) 2015-11-06
BR112014030797A2 (pt) 2017-07-25
JP6440259B2 (ja) 2018-12-19
CA2876020C (en) 2018-08-21
KR20150043289A (ko) 2015-04-22
US20180002382A1 (en) 2018-01-04
CA2943258C (en) 2020-12-22

Similar Documents

Publication Publication Date Title
KR101944263B1 (ko) 에이치비브이 감염 및 관련 질병의 치료를 위한 폴리펩타이드 및 항체
US10940195B2 (en) Vaccines against HPV and HPV-related diseases
CN105669838B (zh) 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体
JP6462599B2 (ja) Ｒｓｖ融合タンパク質のエピトープ及びそのエピトープを認識する抗体
JP2021063092A (ja) Ｂ型肝炎表面抗原に対する抗体及びその使用
RU2585525C2 (ru) Эпитоп поверхностного антигена вируса гепатита b и его применение
NO319466B1 (no) Nukleinsyresekvens kodende intracellulaere bindingsproteiner og defekt, rekombinant virus, vektor, farmasoytisk preparat og anvendelse derav.
CN113717283A (zh) 一种抗乙型肝炎病毒e抗原的单克隆抗体及其应用
KR101839101B1 (ko) B형 간염 바이러스 표면 항원의 에피토프 및 이에 특이적으로 결합하는 b형 간염 바이러스 중화 결합 분자
HK1203978B (en) Polypeptides and antibodies for treating hbv infection and related diseases
US20080075717A1 (en) Antigen Imitating Extracellular Areas of Membrane Proteins of Type III Produced from Intracellular Pathogenic Micro-Organisms, Derived Conformational Antibodies and the Use Thereof
JPH02504284A (ja) 抗原、および、抗イディオタイプ抗体、または抗原に対する細胞受容体に特異的な抗体に共通のアミノ酸配列に由来する免疫原および生物学的活性ペプチド

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150109

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160314

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170821

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180626

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170821

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20180626

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180221

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150319

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20180830

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20180727

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20180626

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20180221

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150319

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
PN2301 Change of applicant

Patent event date: 20181129

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181130

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190128

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220111

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20221229

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20231219

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20241211

Start annual number: 7

End annual number: 7